- Report
- January 2026
- 197 Pages
Global
From €3173EUR$3,545USD£2,772GBP
€3526EUR$3,939USD£3,080GBP
- Report
- January 2026
- 196 Pages
Global
From €3173EUR$3,545USD£2,772GBP
€3526EUR$3,939USD£3,080GBP
- Report
- April 2026
- 299 Pages
Global
From €5237EUR$5,850USD£4,574GBP
- Report
- February 2026
- 250 Pages
Global
From €4019EUR$4,490USD£3,511GBP
- Report
- February 2026
- 306 Pages
Global
From €2238EUR$2,500USD£1,955GBP
- Report
- October 2025
- 160 Pages
Global
From €3005EUR$3,358USD£2,625GBP
€3536EUR$3,950USD£3,088GBP
- Report
- July 2025
- 100 Pages
Global
From €3500EUR$4,189USD£3,164GBP
- Report
- February 2026
- 250 Pages
Global
From €4019EUR$4,490USD£3,511GBP
- Report
- June 2025
- 150 Pages
Global
From €3357EUR$3,750USD£2,932GBP
- Report
- June 2025
- 150 Pages
Global
From €2416EUR$2,699USD£2,110GBP
- Report
- May 2025
- 200 Pages
Global
From €2229EUR$2,490USD£1,947GBP
- Report
- April 2026
- 389 Pages
Global
From €5237EUR$5,850USD£4,574GBP
- Report
- February 2026
- 250 Pages
Global
From €4019EUR$4,490USD£3,511GBP
- Report
- February 2026
- 250 Pages
Global
From €4019EUR$4,490USD£3,511GBP
- Report
- January 2026
- 185 Pages
Global
From €4028EUR$4,500USD£3,519GBP
- Report
- July 2025
- 350 Pages
Global
From €4430EUR$4,949USD£3,870GBP
- Report
- October 2025
- 160 Pages
Global
From €3005EUR$3,358USD£2,625GBP
€3536EUR$3,950USD£3,088GBP
- Report
- April 2025
- 150 Pages
Global
From €4341EUR$4,850USD£3,792GBP
- Report
- April 2025
- 133 Pages
Global
From €16108EUR$17,995USD£14,070GBP
- Report
- April 2025
- 21 Pages
Global
From €16108EUR$17,995USD£14,070GBP

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that affects millions of people worldwide. It is characterized by difficulty breathing, coughing, and wheezing. COPD is typically treated with a combination of medications, including bronchodilators, inhaled corticosteroids, and antibiotics. The COPD drug market is a subset of the larger respiratory drug market, which includes drugs used to treat asthma, allergies, and other respiratory conditions.
The COPD drug market is highly competitive, with a variety of companies offering different types of medications. Some of the major players in the market include GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Novartis, and Merck. These companies offer a range of COPD medications, including bronchodilators, inhaled corticosteroids, and antibiotics. Other companies, such as Teva Pharmaceuticals and Mylan, also offer generic versions of these medications. Show Less Read more